Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note released on Wednesday,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Aprea Therapeutics Trading Up 1.4 %

NASDAQ APRE opened at $3.67 on Wednesday. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The stock has a 50 day moving average price of $3.35 and a 200-day moving average price of $3.46.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, sell-side analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the sale, the director now directly owns 233,651 shares in the company, valued at $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for about 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.